Compare Kinder Morgan Inc (KMI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Sanofi SA — how do they compare? Kinder Morgan Inc trades at $32.49 (market cap $71.81B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 150 Days and Sanofi SA for 94 Days on average.
| KMI | SNY | |
|---|---|---|
Market Cap | $71.81B | $95.18B |
Volume | 16,921,908 | 2,995,646 |
Sector | Energy | Health |
52-Week High | $34.31 | $52.34 |
52-Week Low | $25.84 | $39.51 |
Typical Hold Time | 150 Days | 94 Days |
Enterprise Value | $103.86B | $114.48B |
Dividend Yield | 3.66% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $32.49, up 2.11% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with revenue growth from $15.1B in 2024 to $16.94B in 2025 and net income margin expanding to 19.31%. Recent earnings beats and a $10B project backlog support growth prospects, while analyst consensus targets $37.20 with 47% buy ratings.
KMI presents a compelling investment case with stable fee-based revenues, dividend yield support, and natural gas infrastructure growth. Key risks include energy market volatility and high debt levels ($29.66B long-term). The stock offers upside potential from current levels but requires monitoring of cash flow sustainability and interest rate sensitivity.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
